4,788 shares in Bristol-Myers Squibb (NYSE:BMY) purchased by Register Financial Advisors LLC

Register Financial Advisors LLC purchased a new position in Bristol-Myers Squibb (NYSE:BMY – Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 4,788 shares of the biopharmaceutical company’s stock, valued at approximately $260,000.

A number of other large investors also recently made changes to their positions in BMY. McClarren Financial Advisors Inc. grew its position in Bristol-Myers Squibb by 532.7% during the 4th quarter. McClarren Financial Advisors Inc. now owns 1,879 shares of the biopharmaceutical company’s stock valued at $96,000 after purchasing an additional 1,582 shares during the period. Institute for Wealth Management LLC. boosted its holdings in Bristol-Myers Squibb by 1.0% in the fourth quarter. Institute for Wealth Management LLC. now owns 30,056 shares of the biopharmaceutical company’s stock worth $1,542,000 after buying an additional 296 shares during the period. Great Diamond Partners LLC boosted its position in Bristol-Myers Squibb by 9.2% during the 4th quarter. Great Diamond Partners LLC now owns 4,372 shares of the biopharmaceutical company’s stock valued at $224,000 after acquiring an additional 367 shares in the last quarter. Global Assets Advisory LLC purchased a new position in shares of Bristol-Myers Squibb in the first quarter worth about $5,161,000. Finally, Principal Securities Inc. bought a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at approximately $1,139,000. 76.41% of shares are currently owned by institutional investors.

Changes in Analyst Ratings

Several equities research analysts recently weighed in on the company. Barclays cut their price target on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research note on Friday, April 26th. StockNews.com cut shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Thursday. BMO Capital Markets cut their price objective on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research note on Friday, April 26th . Societe Generale downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. Finally, William Blair reissued a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have issued a buy rating to the stock. Bristol-Myers Squibb currently has an average rating of “Hold” and a consensus price target of $60.00, according to MarketBeat .

Check out our latest research report on BMY

Bristol-Myers Squibb Price Performance

NYSE BMY opened at $41.53 on Friday. The stock has a market cap of $84.19 billion, a price-to-earnings ratio of -13.40, a PEG ratio of 14.54 and a beta of 0.43. Bristol-Myers Squibb has a 1-year low of $39.63 and a 1-year high of $65.38. The company has a debt-to-equity ratio of 2.99, a current ratio of 1.11, and a quick ratio of 0.99. The company’s fifty day moving average price is $42.97 and its 200 day moving average price is $48.16.

Bristol-Myers Squibb (NYSE:BMY – Get Your Free Report ) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.53) by $0.13. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The company had revenue of $11.87 billion during the quarter, compared to the consensus estimate of $11.45 billion. During the same period in the previous year, the company posted EPS of $2.05. The company’s quarterly revenue was up 4.7% compared to the same quarter last year. On average, equities analysts forecast that Bristol-Myers Squibb will post 0.58 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, August 1st. Stockholders of record on Friday, July 5th will be paid a dividend of $0.60 per share. This represents a dividend of $2.40 on an annualized basis and a dividend yield of 5.78%. The ex-dividend date is Friday, July 5. Bristol-Myers Squibb’s payout ratio is -77.42%.

Bristol-Myers Squibb Company Profile

(Free Report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic and neuroscience. The company’s products include Eliquis for reducing the risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anticancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Featured Articles

Want to see what other hedge funds BMY owns? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY – Free Report).

Get news and reviews for Bristol-Myers Squibb Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bristol-Myers Squibb and related companies with MarketBeat.com’s FREE daily email newsletter.